Research report
Induction of antibodies against human prion proteins (PrP) by DNA-mediated immunization of PrP00 mice

https://doi.org/10.1016/S0022-1759(96)00165-2Get rights and content

Abstract

Prion diseases are neurodegenerative disorders, affecting humans and animals. The human diseases include kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI). To generate monospecific antisera against human prion proteins we have immunized mice with DNA coding for different human prion proteins. We constructed immunization vectors expressing individual genotypes of either the cellular prion gene (PRNP) or mutant forms under appropriate promoters. This approach avoids the preparation of infectious material for immunization. To circumvent immunological tolerance prion protein-deficient PrP00 mice were used for the DNA-mediated immunization. Thereby monospecific sera were raised capable of specifically precipitating in vitro synthesized human prion proteins. With prion protein-specific peptide ELISAs, we found that antibodies are predominantly directed against the octapeptide repeat region and to a lesser extent to regions comprising the signal peptide, the neurotoxic domain or the GPI anchor. In contrast, prion gene-positive (PrP+/+) BALB/c mice immunized under the same experimental conditions as the PrP00 mice did not respond with antibody formation against the human prion protein. This is the first report clearly showing that immune competent prion protein-deficient mice react with a vigorous polyclonal immune response after DNA-mediated immunization with human prion gene sequences.

References (22)

  • R. Gabizon et al.

    Immunoaffinity purification and neutralization of scrapie prion infectivity

  • Cited by (58)

    • A seven-residue deletion in PrP leads to generation of a spontaneous prion formed from C-terminal C1 fragment of PrP

      2020, Journal of Biological Chemistry
      Citation Excerpt :

      Each mutant construct was verified by sequencing. The anti-PrP mAbs used were as follows: 4F2 directed to the octa-repeat domain (residues 62–94 according to sheep PrP numbering) (61, 62), 12B2 (residues 93–97) (63), 8G8 (residues 100–105) (61, 62), 6C2 (residues 114–121) (64) (Central Veterinary Institute, Wageningen University & Research, Wageningen, The Netherlands) Sha31 (residues 148–155) (62) (Bertin Pharma), and 8F9 (residues 224–234) (65). Sha31and 8G8 were biotinylated and further detected with horseradish peroxidase–conjugated streptavidin.

    • Generation and characterization of polyclonal antibodies against mouse T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory domain by DNA-based immunization

      2014, Transplantation Proceedings
      Citation Excerpt :

      The mTIGIT sequence was inserted into the multiple clone sites of pGM-T using a pGM-T clone kit (Tiangen, Beijing, China). The corresponding ligated products were digested with EcorI and XhoI, and then cloned into the commercially available mammalian expression vector pcDNA3.1 (+) [8–10]. The recombinant plasmids were transformed into Escherichia coli TOP10 cells (Tiangen, Beijing, China) to screen out the positive clone on LB agar with ampicillin resistance (100 μg/mL).

    • Rapid screening and confirmatory methods for biochemical diagnosis of human prion disease

      2011, Journal of Virological Methods
      Citation Excerpt :

      The monoclonal antibodies used in these assays were selected for their sensitive detection of the PK-treated and denatured PrP. The capture antibody 3B5 recognises the octarepeat region of PrP (Krasemann et al., 1996, 1999), while the tracer antibody 12F10 binds to the core part of the protein (Feraudet et al., 2005). PK digestion is carried out in a controlled concentration and a controlled medium (mixture of detergent and chaotropic agents) to preserve the N-terminal epitope.

    View all citing articles on Scopus
    View full text